

Monday, February 16

08:30 Bus departs from Stockholm Cityterminalen

09:15 Arrival, coffee and registration

09:45 - 10:10 **Welcome**

Elias Arnér, Dhifaf Sarhan and Ninib Baryawno

Morning Session 1

Chair: **Nikolas Herold**

10:10 – 10:20 **Klas Wiman**, Department of Oncology-Pathology

Cancer precision medicine by targeting missense and nonsense mutant TP53

10:25 – 10:35 **Taras Kreslavsky**, Department of Medicine, Solna

Dissection of gamma-delta T cell antigen specificities in health and disease

10:40 – 10:50 **Antonino Cassotta**, Department of Medicine, Huddinge

Mapping myeloma-reactive T cells to develop novel adoptive cell therapies for multiple myeloma

10:55 – 11:05 **Xiaofei Li**, Department of Neurobiology, Care Sciences and Society

Targeting the Untargetable: A Novel Approach to Pediatric Ependymoma Therapy

11:10 – 11:40 **Coffee Break**

Morning Session 2

Chair: **Hanna Brauner**

11:40 – 11:50 **Alexios Matikas**, Department of Oncology-Pathology

Investigating the effect of (neo)adjuvant chemotherapy for early breast cancer: clinical and molecular correlations

11:55 – 12:05 **Marie Arsenian Henriksson**, Department of Microbiology, Tumor and Cell Biology

Metabolic reprogramming by MYC inhibition as precision medicine in clear cell renal carcinoma and childhood neuroblastoma

12:10 – 12:50 Patient perspective and involvement in research

Lise-lott Eriksson, Cancer Research KI Executive Board member, Founder and Chair of Blodcancerforum

Sophie Werkö, Patient representative, Cancer Research KI Research WG member, Director for International Relations at SBU

Andri Papakonstantinou, Department of Oncology-Pathology

12:50 – 13:00 Group Photo**13:00 – 14:00 Lunch****Afternoon Session 1**

Chair: **Fredrik Wermeling**

14:00 – 14:10 Carmen Gerlach, Department of Medicine, Solna

From T cell subsets to axes of diversification – a novel conceptual framework for T cell diversification

14:15 – 14:25 Tomas Sjöberg Bexelius, Department of Women's and Children's Health

Molecular clock disruption and its consequence in childhood cancer, neuroblastoma

14:30 – 14:40 Ana Teixeira, Department of Physiology and Pharmacology

Mapping Her2 nanodomains in breast cancer cells

14:45 – 14:55 Nikolas Herold, Department of Women's and Children's Health

Deciphering drug-drug interactions in paediatric oncology

15:00 – 15:45 Coffee Break and Check-in**Afternoon Session 2**

Chairs: **Dhifaf Sarhan** and **Ninib Baryawno**

15:45 – 16:45 The gender perspective: inequalities in research

Mia von Knorring, Associate Professor in healthcare organization and program director for the FIELD program (Fellows in Gender Equal Career Development), Department of Learning, Informatics, Management and Ethics

Kristina Ullgren, Equal Opportunities strategist & Coordinator, HR-office at KI

16:45 – 16:55 **Mikael Karlsson**, Department of Microbiology, Tumor and Cell Biology
Targeting immune cells in the tumor microenvironment to develop cure for cancer

17:00 – 17:10 **Fang Fang**, Institute of Environmental Medicine
Co-occurrence of cancer after mental disorders, phenotypic correlation, family coaggregation, genetic and environmental contribution

17:15 – 17:30 **Coffee Break**

Afternoon Session 3

Chair: Ourania Kostopoulou

17:30 – 17:40 **Elinor Nemlander**, Department of Neurobiology, Care Sciences and Society
The Stockholm Early Detection of Cancer Study (STEADY-CAN): expanding a population-based cohort to integrate sociodemographic and biomarker data for research on early cancer detection

17:45 – 17:55 **Tom Erkers**, Department of Oncology-Pathology
Functional Precision Medicine in Blood Cancers

18:00 – 18:10 **Hans Grönlund**, Department of Clinical Neuroscience
Bead-bound, personal neoantigens expand T cells from tumor regional lymph nodes (rLN) in colorectal cancer

18:15 – 18:30 **Patrik Blomquist**, KI Innovations
Venture building at KI

18:30 – 19:00 **Elevator Pitches**
Chair: Twana Alkasalias

Anita Göndör
Laszlo Szekely
Isabel Barragan
Karin Sundström
Erik Benson
Elias Arnér
Oscar Bedoya Reina
Hanna Brauner

19:00 – 20:00 **Mingle** (finger food available)

20:00 **Dinner**, followed by continued mingle

Tuesday, February 17

07:30 – 08:30 Breakfast and Check-out

Morning Session 1

Chair: **Ioannis Zerdeis**

08:30 – 09:15 **Infrastructure at KI and SciLifeLab: How to Leverage What We Have and Build What We Need**

Karin Dahlman-Wright, Chair of the KI board of infrastructure

Lars Holmgren, Director of integration, SciLifeLab

09:15 – 09:25 **Susanne Gabrielsson**, Department of Medicine, Solna

Eliminating PD-L1 on dendritic cell extracellular vesicles for immunotherapy potentiates immune-mediated tumor rejection in mice

09:30 – 09:40 **Thomas Müller**, Department of Medicine, Huddinge

Tissue origin shapes human CD8+ T cell cytotoxicity

09:45 – 09:55 **Ingemar Ernberg**, Department of Microbiology, Tumor and Cell Biology

Rethinking cancer: unresolved enigmas in understanding the biology of nasopharyngeal carcinoma (NPC)

10:00 – 10:30 **Coffe Break**

Morning session 2

Chair: **Brinton Seashore-Ludlow**

10:30 – 10:40 **Rainer Heuchel**, Department of Clinical Science, Intervention and Technology

Heterospheroid cell culture to identify new treatment options for pancreatic ductal adenocarcinoma

10:45 – 10:55 **Andreas Lennartsson**, Department of Medicine, Huddinge

Targeting Epigenetic and Transcriptional vulnerabilities in AML

11:00 – 11:10 **Mikael Benson**, Department of Clinical Science, Intervention and Technology

High-resolution computational models to prioritise early mechanisms, biomarkers and drug targets in malignant transformation

11:15 – 11:25 **Staffan Strömbäck**, Department of Medicine, Huddinge

Mechanical regulation of cancer development and progression

11:30 – 12:30 **Lunch**

Afternoon Session 1

Chair: **Magdalena Paolino**

12:30 – 12:40 **Johan Hartman**, Department of Oncology-Pathology
Characterization of ER-low expressing breast cancers

12:45 – 12:55 **Helene Rundqvist**, Department of Laboratory Medicine
Exercise training reshapes the systemic immune environment in patients with metastatic breast cancer: results from the PREFERABLE-EFFECT multi-centre randomised-controlled trial

13:00 – 13:10 **Joakim Dillner**, Department of Clinical Science, Intervention and Technology
Center for Cervical Cancer Elimination: Advancing Strategies for HPV-Based Prevention

13:15 – 13:45 **Coffee Break**

13:45 – 15:15 **Funding Landscape and Opportunities**
Chairs: **Dhifaf Sarhan** and **Ninib Baryawno**

Mariette Nordzell, Head of Unit, Research & Education,
Barncancerfonden

Annina Graan, Head of Research Funding & **Joanna Bruzelius**,
Research Funding Officer, *Cancerfonden*

Magdalena Nilsson, Secretary General & **Mariann Eklund**, Economy Case Officer, *Radiumhemmets Forskningsfonder*

15:15 – 15:30 **Conclusion**

16:00 Bus departs to Stockholm Cityterminalen